These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 9261533

  • 21. Prophylaxis for paclitaxel hypersensitivity reactions.
    Kintzel PE.
    Ann Pharmacother; 2001 Sep; 35(9):1114-7. PubMed ID: 11573863
    [Abstract] [Full Text] [Related]

  • 22. Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II trial comparing two schedules.
    Hainsworth JD, Greco FA.
    Cancer; 1994 Aug 15; 74(4):1377-82. PubMed ID: 7914470
    [Abstract] [Full Text] [Related]

  • 23. Successful re-treatment with taxol after major hypersensitivity reactions.
    Peereboom DM, Donehower RC, Eisenhauer EA, McGuire WP, Onetto N, Hubbard JL, Piccart M, Gianni L, Rowinsky EK.
    J Clin Oncol; 1993 May 15; 11(5):885-90. PubMed ID: 8098057
    [Abstract] [Full Text] [Related]

  • 24. Retrospective evaluation of weekly paclitaxel hypersensitivity reactions reported utilizing an electronic medical record system at a tertiary cancer center.
    Lal LS, Gerber DL, Lau J, Dana W.
    Support Care Cancer; 2009 Oct 15; 17(10):1311-5. PubMed ID: 19184123
    [Abstract] [Full Text] [Related]

  • 25. Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions.
    Köppler H, Heymanns J, Weide R.
    Onkologie; 2001 Jun 15; 24(3):283-5. PubMed ID: 11455223
    [Abstract] [Full Text] [Related]

  • 26. Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration.
    Braverman AS, Rao S, Salvatti ME, Adamson B, McManus M, Pierre S.
    Chemotherapy; 2005 May 15; 51(2-3):116-9. PubMed ID: 15886470
    [Abstract] [Full Text] [Related]

  • 27. Randomized, Controlled Trial of Dexamethasone Versus Dexamethasone Plus Hydrocortisone as Prophylaxis for Hypersensitivity Reactions Due to Paclitaxel Treatment for Gynecologic Cancer.
    Jeerakornpassawat D, Suprasert P.
    Int J Gynecol Cancer; 2017 Oct 15; 27(8):1794-1801. PubMed ID: 28704328
    [Abstract] [Full Text] [Related]

  • 28. Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer.
    Jerzak KJ, Deghan Manshadi S, Ng P, Maganti M, McCuaig JM, Bulter M, Oza A, Mackay HJ.
    J Oncol Pharm Pract; 2018 Mar 15; 24(2):83-90. PubMed ID: 27856924
    [Abstract] [Full Text] [Related]

  • 29. The added value of H2 antagonists in premedication regimens during paclitaxel treatment.
    Cox JM, van Doorn L, Malmberg R, Oomen-de Hoop E, Bosch TM, van den Bemt PMLA, Boere IA, Jager A, Mathijssen RHJ, van Leeuwen RWF.
    Br J Cancer; 2021 May 15; 124(10):1647-1652. PubMed ID: 33762718
    [Abstract] [Full Text] [Related]

  • 30. Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.
    Parinyanitikul N, Tanpipattanakul W, Poovorawan N, Rattananupong T, Laoitthi P, Sithidetphaiboon P, Thanasanvimon S, Sriuranpong V.
    Support Care Cancer; 2018 Jul 15; 26(7):2471-2477. PubMed ID: 29435713
    [Abstract] [Full Text] [Related]

  • 31. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.
    Rosenberg P, Andersson H, Boman K, Ridderheim M, Sorbe B, Puistola U, Parö G.
    Acta Oncol; 2002 Jul 15; 41(5):418-24. PubMed ID: 12442916
    [Abstract] [Full Text] [Related]

  • 32. Impact of institutional interventions on the rate of paclitaxel hypersensitivity reactions.
    Jao ME, Indorf AL, Segal EM, Miske A, Eaton KD, Marsolini T, Ghuman S.
    J Oncol Pharm Pract; 2024 Jan 15; 30(1):105-111. PubMed ID: 37021579
    [Abstract] [Full Text] [Related]

  • 33. Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer.
    Yahata H, Saito M, Sendo T, Itoh Y, Uchida M, Hirakawa T, Nakano H, Oishi R.
    Int J Cancer; 2006 May 15; 118(10):2636-8. PubMed ID: 16353140
    [Abstract] [Full Text] [Related]

  • 34. Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
    Berger MJ, Dunlea LJ, Rettig AE, Lustberg MB, Phillips GS, Shapiro CL.
    Support Care Cancer; 2012 Sep 15; 20(9):1991-7. PubMed ID: 22089428
    [Abstract] [Full Text] [Related]

  • 35. Histamine release during rapid vancomycin administration.
    Renz C, Lynch J, Thurn J, Moss J.
    Inflamm Res; 1998 Sep 15; 47 Suppl 1():S69-70. PubMed ID: 9561421
    [No Abstract] [Full Text] [Related]

  • 36. Treatment of recurrent Kaposi's sarcoma of an AIDS patient with weekly paclitaxel.
    Hsu CH, Chen MY, Cheng AL.
    Anticancer Res; 2000 Sep 15; 20(2B):1159-61. PubMed ID: 10810414
    [Abstract] [Full Text] [Related]

  • 37. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.
    Hurwitz CA, Strauss LC, Kepner J, Kretschmar C, Harris MB, Friedman H, Kun L, Kadota R.
    J Pediatr Hematol Oncol; 2001 Sep 15; 23(5):277-81. PubMed ID: 11464982
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.